Skip to main content

Bristol-Myers Squibb Company(BMY-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low58.35
Day High59.21
Open:58.86
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Bristol Myers Squibb: Low Volatility Meets High Dividend Yield
Motley Fool
3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery
Tipranks
Bernstein Remains a Hold on Bristol-Myers Squibb (BMY)
Tipranks
Bristol-Myers Squibb (BMY) Receives a Buy from Barclays
StockStory
1 Unpopular Stock That Should Get More Attention and 2 We Question
CAT
Zacks Investment Research
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
GlobeNewswire
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
Motley Fool
2 Healthcare Stocks to Buy and 1 to Approach With Caution
Zacks Investment Research
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings
Zacks Investment Research
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
Will Keytruda Continue to Aid Merck's Top Line in Q1 Earnings?
Tipranks
Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
Motley Fool
Which Dividend Pharma Stock Should a Value Investor Choose Today?
Tipranks
Bristol-Myers Squibb (BMY) Gets a Hold from RBC Capital
Zacks Investment Research
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock?
Motley Fool
2 Recession Resistant Dividend Stocks to Buy Now While They're Still Cheap
Tipranks
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Vor Biopharma (VOR) and Bristol-Myers Squibb (BMY)
Quiver Quantitative, Inc.
Gilead to Acquire Tubulis for Up to $5 Billion to Expand Cancer Drug Pipeline
Tipranks
BMY Extends Admilparant Program, Reinforcing Its Bet on Pulmonary Fibrosis
Tipranks
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY)
Tipranks
Bristol-Myers Squibb (BMY) Gets a Buy from Piper Sandler
Tipranks
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Bristol-Myers Squibb (BMY)
Tipranks
Bristol-Myers Squibb (BMY) Gets a Hold from Erste Group
StockStory
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know
AMN
Tipranks
Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo
StockStory
3 Value Stocks Walking a Fine Line
UTZ
Tipranks
Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY)
StockStory
1 Surging Stock with Impressive Fundamentals and 2 That Underwhelm
TLYS
Zacks Investment Research
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
Can Gilead's Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
StockStory
Stocks making big moves yesterday: Robinhood, Payoneer, Micron, Limbach, and Bristol-Myers Squibb
HOOD
StockStory
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
BMY
Zacks Investment Research
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Will the Recent Label Expansion of BMY's Opdivo Boost Its IO Franchise?
Motley Fool
What Is Considered a Good Stock Dividend? 2 Healthcare Stocks Fit the Bill.

Profile

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.